Frédéric Féru

685 total citations
8 papers, 453 citations indexed

About

Frédéric Féru is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Frédéric Féru has authored 8 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Cell Biology. Recurrent topics in Frédéric Féru's work include Melanoma and MAPK Pathways (3 papers), Peptidase Inhibition and Analysis (2 papers) and Neuroscience and Neuropharmacology Research (2 papers). Frédéric Féru is often cited by papers focused on Melanoma and MAPK Pathways (3 papers), Peptidase Inhibition and Analysis (2 papers) and Neuroscience and Neuropharmacology Research (2 papers). Frédéric Féru collaborates with scholars based in United States, United Kingdom and France. Frédéric Féru's co-authors include Thomas W. Gero, David A. Scott, Nathanael S. Gray, Pasi A. Jänne, Eric S. Fischer, Kenneth D. Westover, Lianbo Li, Chunshan Quan, Yuan Xiong and Yuanhua Ding and has published in prestigious journals such as Bioorganic & Medicinal Chemistry Letters, Cell chemical biology and Chemical Biology & Drug Design.

In The Last Decade

Frédéric Féru

8 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frédéric Féru United States	7	396	172	60	59	56	8	453
Devin J. Noblin United States	6	567 1.4×	210 1.2×	64 1.1×	85 1.4×	50 0.9×	6	619
Sarah E. Dixon-Clarke United Kingdom	5	357 0.9×	208 1.2×	55 0.9×	24 0.4×	47 0.8×	5	444
Lynsey Fazal United Kingdom	8	216 0.5×	96 0.6×	83 1.4×	27 0.5×	66 1.2×	16	330
Yu-Gang Song China	4	440 1.1×	200 1.2×	29 0.5×	101 1.7×	28 0.5×	10	519
Liv Johannessen United States	8	241 0.6×	152 0.9×	27 0.5×	24 0.4×	42 0.8×	19	374
Jacob I. Contreras United States	10	344 0.9×	195 1.1×	61 1.0×	80 1.4×	124 2.2×	12	536
Hojong Yoon South Korea	12	466 1.2×	178 1.0×	22 0.4×	79 1.3×	87 1.6×	19	563
Corynn Kasap United States	6	253 0.6×	115 0.7×	34 0.6×	214 3.6×	61 1.1×	12	490
Juran Kato‐Stankiewicz United States	7	347 0.9×	169 1.0×	54 0.9×	16 0.3×	40 0.7×	9	484
Mamatha Reddy United States	6	199 0.5×	159 0.9×	58 1.0×	43 0.7×	78 1.4×	9	346

Countries citing papers authored by Frédéric Féru

Since Specialization

Citations

This map shows the geographic impact of Frédéric Féru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Féru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Féru more than expected).

Fields of papers citing papers by Frédéric Féru

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Féru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Féru. The network helps show where Frédéric Féru may publish in the future.

Co-authorship network of co-authors of Frédéric Féru

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Féru. A scholar is included among the top collaborators of Frédéric Féru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Féru. Frédéric Féru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Gero, Thomas W., David E. Heppner, Tyler S. Beyett, et al.. (2022). Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. Bioorganic & Medicinal Chemistry Letters. 68. 128718–128718. 13 indexed citations

2.

Li, Zhengnian, Chelsea E. Powell, Brian J. Groendyke, et al.. (2020). Discovery of a series of benzopyrimidodiazepinone TNK2 inhibitors via scaffold morphing. Bioorganic & Medicinal Chemistry Letters. 30(19). 127456–127456. 4 indexed citations

3.

Groendyke, Brian J., Chelsea E. Powell, Frédéric Féru, et al.. (2020). Benzopyrimidodiazepinone inhibitors of TNK2. Bioorganic & Medicinal Chemistry Letters. 30(4). 126948–126948. 8 indexed citations

4.

Xiong, Yuan, Nozhat Safaee, Radosław P. Nowak, et al.. (2019). Exploring Targeted Degradation Strategy for Oncogenic KRASG12C. Cell chemical biology. 27(1). 19–31.e6. 207 indexed citations

5.

Lu, Jia, Lianbo Li, Frédéric Féru, et al.. (2017). Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell chemical biology. 24(8). 1005–1016.e3. 101 indexed citations

6.

Liu, Hu, Cyrille Kuhn, Frédéric Féru, et al.. (2010). Enhanced selectivity profile of pyrazole-urea based DFG-out p38α inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(16). 4885–4891. 9 indexed citations

7.

Kothe, Michael, Darcy Kohls, Simon Low, et al.. (2007). Research Article: Selectivity‐determining Residues in Plk1. Chemical Biology & Drug Design. 70(6). 540–546. 95 indexed citations

8.

Auclair, Eric, et al.. (2000). Synthesis and structure–activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 10(1). 35–38. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact